Wave Life Sciences Launched Obesity Clinical Trial
The Phase 2a trial tests WVE-007 alongside tirzepatide for patients managing obesity and type 2 diabetes.
Updated on Sept. 23, 2026 in Weight Loss
Live Poll
Do you trust that newer obesity treatments will prioritize preserving muscle mass over simple weight loss?
Wave Life Sciences has initiated a Phase 2a clinical trial evaluating its investigational therapy WVE-007 in combination with tirzepatide. The study focuses on individuals living with obesity and type 2 diabetes.
Why it matters
The INLIGHT clinical program aims to determine if WVE-007 can improve fat loss and preserve muscle mass more effectively than existing incretin treatments alone. This approach could broaden the therapeutic options available for chronic metabolic conditions.
The clinical trial evaluates 240 mg and 400 mg doses of WVE-007 in a placebo-controlled environment. Participants are selected based on a body mass index ranging between 35 and 50 kg/m2.
The players
Wave Life Sciences
Headquartered in Cambridge, Massachusetts, this clinical-stage biotechnology company focuses on developing genetic medicines.
The details
The trial combines the GalNAc-siRNA drug candidate WVE-007 with weekly doses of tirzepatide to assess performance through the company's INLIGHT program. Researchers are investigating the potential for these treatments to support metabolic health across multiple disease profiles.
Timeline
Wave Life Sciences presented preclinical data at ObesityWeek in 2025.
The Phase 2a clinical trial was initiated on September 23, 2026.
A maintenance therapy clinical trial is scheduled for the second half of 2026.
The Big Picture
The trial is part of the INLIGHT clinical program, which focuses on developing new treatments for metabolic disorders. This specific study extends the scope of the program by testing WVE-007 in combination with established incretin therapies.
This trial offers a new pathway for patients currently managing obesity and type 2 diabetes with standard incretin treatments. Results from this study will help determine if future combination therapies can provide better outcomes for weight management and muscle preservation.
The takeaway
This trial represents a shift toward combination therapies that aim to move beyond simple weight loss by focusing on muscle preservation. Patients and providers should monitor future clinical results to understand how these findings might eventually influence metabolic care standards.
What happens next
Wave Life Sciences plans to initiate a post-incretin maintenance therapy clinical trial in the second half of 2026.
Further reading
For more information on current developments in this field, visit the Weight Loss section.
Live Poll
Do you trust that newer obesity treatments will prioritize preserving muscle mass over simple weight loss?
